The 5-Lipoxygenase Inhibitor Zileuton Protects Pressure Overload-Induced Cardiac Remodeling via Activating PPARα

Figure 5

5-LOX silencing relieves cardiomyocyte hypertrophy. (a) Expression level of 5-LOX in heart tissue at 8 weeks after AB surgery (, vs. the sham group). (b) Expression level of 5-LOX in cardiomyocytes 24 h after PE stimulation (, vs. the control group). (c–g) Cells were transfected with 5-LOX siRNA for 8 h and then stimulated with PE for 24 h. (c) Expression level of 5-LOX after transfection with 5-LOX siRNA (). (d) α-Actinin staining () and quantification of cells. (e) Transcription levels of hypertrophic markers in H9c2 cells (). (f) ROS levels (). (g) Activities of SOD, Gpx, and NADPH oxidase (). vs. the ScRNA-PBS group; ^# vs. the ScRNA-PE group.

(a)

(b)

(c)

(d)

(e)

(f)

(g)